Navigating 11 Analyst Ratings For 10x Genomics
Navigating 11 Analyst Ratings For 10x Genomics
瀏覽10x genomics的11個分析師評級
During the last three months, 11 analysts shared their evaluations of 10x Genomics (NASDAQ:TXG), revealing diverse outlooks from bullish to bearish.
在過去的三個月中，11位分析師分享了他們對10x Genomics（納斯達克股票代碼：TXG）的評估，揭示了從看漲到看跌的不同前景。
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
下表概述了他們最近的評級，簡要介紹了過去30天中不斷變化的情緒，並將其與前幾個月進行了比較。
Analysts have recently evaluated 10x Genomics and provided 12-month price targets. The average target is $26.0, accompanied by a high estimate of $46.00 and a low estimate of $16.00. A 35.0% drop is evident in the current average compared to the previous average price target of $40.00.
分析師最近對10x Genomics進行了評估，並提供了12個月的價格目標。平均目標爲26.0美元，最高估計值爲46.00美元，低估值爲16.00美元。與之前的平均目標股價40.00美元相比，當前的平均價格下降了35.0％。
Interpreting Analyst Ratings: A Closer Look
解讀分析師評級：仔細觀察
The analysis of recent analyst actions sheds light...
對分析師近期行爲...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。